Clinical trial
Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung…
NCT00065429 · ImmunoGen, Inc., Industry · Completed
Key facts
| NCT number | NCT00065429 |
|---|---|
| Title | Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer |
| Official title | A Phase I, Open-Label, Dose Escalation Study of Weekly Dosing With BB-10901, Followed by a Phase II Efficacy Expansion |
| Lead sponsor | ImmunoGen, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | BB-10901 |
| Enrollment | 64 |
| Start date | Apr 1, 2003 |
| Primary completion | Nov 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jul 24, 2003 |
| Last update posted | Jul 18, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: